<DOC>
	<DOCNO>NCT01722968</DOCNO>
	<brief_summary>To explore molecular biomarkers and/or gene expression signatures predict response bevacizumab give combination paclitaxel first line therapy HER2 negative metastatic breast cancer ( MBC ) .</brief_summary>
	<brief_title>A Biomarker Study Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab Paclitaxel</brief_title>
	<detailed_description>This prospective , randomize , 2-arm , open-label , single-center , phase II trial . A total 30 patient include period 2 year . The study initiate non-randomized , feasibility stage include ten patient treat bevacizumab paclitaxel , order determine safety metastatic tumor biopsy therapy bevacizumab . In second phase , patient randomize ( 1:1 ) two treatment arm : A. Bevacizumab + paclitaxel B. Paclitaxel</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>1 . Age 1870 year . 2 . Performance status ECOG 02 . 3 . Clinically / radiologically proven stage IV recurrent HER2 negative breast cancer . 4 . At least one tumor lesion accessible biopsy . This lesion may treat previously irradiation . 5 . Clinically and/or radiographically document measurable disease accord RECIST v1.1 criterion . At least one site disease must unidimensionally measurable follow : 1 . CTscan , physical exam ≥ 10 mm } Chest Xray ≥ 20 mm } see Eisenhauer et al . detail 2 . Lymph node short axis ≥ 15 mm } 3 . All radiology study must perform within 28 day prior registration ( 35 day negative ) . 6 . Adequate bonemarrow , hepatic renal function define laboratory test within 7 day prior enrollment : 1 . Haematology : Absolute granulocytes &gt; 1.5 x 109/L Platelets &gt; 100 x 109/L 2 . Biochemistry : Bilirubin within normal limit Serum creatinine within normal limit 7 . APTT INR within normal limit within 7 day prior enrollment . 8 . Adequate cardiac function Left Ventricular Ejection Fraction ( LVEF ) within normal limit determine echocardiogram MUGA within 28 day prior inclusion . 9 . Written informed consent must give . 1 . Previous systemic treatment MBC . 2 . Major surgery le 28 day prior enrollment . 3 . Concurrent malignancy site , except adequately control limited basal cell carcinoma squamouscell carcinoma skin carcinoma situ cervix . 4 . Bleeding diathesis , history thromboembolic disease , ongoing treatment warfarin , heparin analog antiplatelet drug . 5 . Major cardiac comorbidity . 6 . Previous treatment bevacizumab . 7 . Previous allergic reaction taxane analog . 8 . Ongoing pregnancy lactation . 9 . Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Metastatic breast cancer</keyword>
</DOC>